Application of transient elastography combined with serological markers to distinguish early hepatic fibrosis of chronic hepatitis B
10.3969/j.issn.1673-9701.2023.34.005
- VernacularTitle:瞬时弹性成像技术联合血清学标志物评估慢性乙型肝炎早期肝纤维化的应用研究
- Author:
Jiqing LIU
1
;
Jianfeng BAO
;
Bin HUANG
Author Information
1. 浙江中医药大学附属杭州西溪医院特检科,浙江杭州 310023
- Keywords:
Hepatitis B;
Transient elastography;
Serological marker;
Fat attenuation index;
Liver stiffness measurement
- From:
China Modern Doctor
2023;61(34):19-23
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical value of transient elastography(TE)combined with serological markers to distinguish early hepatic fibrosis of chronic hepatitis B(CHB).Methods Clinical data of 176 CHB patients admitted to Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University from January 2020 to November 2022 were retrospectively analyzed,and the included patients were divided into training group(n=123)and test group(n=53).Based on the data of the training group,the clinical features were screened by the least absolute shrinkage and selection operator algorithm,and the early liver fibrosis model was constructed by multivariate Logistic regression.The performance of the model was evaluated using test group data and receiver operating characteristic(ROC)curve.Finally,the stability and clinical efficacy of the model were evaluated using calibration curve and decision curve,respectively.Results The prediction model was constructed based on liver stiffness measurement,fat attenuation index,red blood cells and glutamic-oxaloacetic transaminase.The area under the curve of the model in training group and test group was 0.824 and 0.819,the sensitivity was 82.1%and 80.6%,and the specificity was 71.8%and 68.8%,respectively.The calibration curve showed good calibration performance in training group and test group,and the decision curve showed good clinical efficacy of the model in training group and test group.Conclusion A hybrid model of TE technology combined with serological markers provides a potential new way to identify early liver fibrosis in patients with CHB,which could aid in clinical monitoring and treatment.
